Suscribirse

Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern - 05/04/22

Doi : 10.1016/j.jaci.2022.01.013 
Eliott Lafon, MSc a, Michael Jäger, MSc a, Angelika Bauer, MD b, Markus Reindl, PhD b, Rosa Bellmann-Weiler, MD c, Doris Wilflingseder, PhD a, Cornelia Lass-Flörl, MD a, Wilfried Posch, PhD a,
a Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria 
b Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria 
c Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria 

Corresponding author: Wilfried Posch, PhD, Medical University of Innsbruck, Institute of Hygiene and Medical Microbiology, Schöpfstrasse 41/R311, 6020 Innsbruck, Austria.Medical University of InnsbruckInstitute of Hygiene and Medical MicrobiologySchöpfstrasse 41/R311Innsbruck6020Austria

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Few studies have directly compared virus-specific antibodies and their neutralizing capacity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wild type (WT) and circulating variants of concern despite the reported high efficacy of messenger RNA (mRNA)- and vector-based vaccines.

Objective

We assessed SARS-CoV-2 spike protein region 1 (S1)-specific antibodies of BNT162b2, mRNA-1273, and ChAdOx1 vaccinated as well as convalescent coronavirus disease 2019 (COVID-19) patients. We also determined the neutralization ability against SARS-CoV-2 WT and B.1.1.7 (Alpha), B1.1.7 E484K (Alpha-E484K), B.1.351 (Beta), and B.1.617.2 (Delta) variants.

Methods

Serum samples of 107 fully vaccinated or convalescent individuals were analyzed for anti–SARS-CoV-2-S1 IgG and IgA as well as for total anti–SARS-CoV-2 receptor binding domain Ig. Furthermore, neutralization capacity as 50% and 90% neutralization titer values against SARS-CoV-2 WT virus and circulating variants were determined.

Results

We observed a robust IgG response in all participants; however, the highest titers were detected in mRNA-based vaccine recipients. In case of serum IgA responses, the difference between mRNA- and vector-based vaccines or convalescent patients was even more pronounced. Interestingly, all 3 vaccines could neutralize all tested variants of concern in addition to WT virus, but in some individuals, only low or no neutralization, especially against Alpha-E484K and the Delta variant, was detected.

Conclusion

Our study of the efficacy of various COVID-19 vaccines found that mRNA-1273 had the highest neutralization abilities compared to BNT162b2 and ChAdOx1. COVID-19 convalescent patients demonstrated the most heterogeneous range of antibody titers and neutralization abilities, making it hard to assess protection. Furthermore, a significant positive relation between antibodies and the 50% neutralization titer values for immunized and convalescent individuals was determined.

El texto completo de este artículo está disponible en PDF.

Key words : SARS-CoV-2, variants of concern, vaccines, IgG and IgA antibodies, virus neutralization

Abbreviations used : Ab, BAU, BNT162b2, ChAdOx1, CI, COVID-19, mRNA, mRNA-1273, NT50, NT90, RBD, RoA, S1, SARS-CoV-1/2, VOC, WT


Esquema


 The first 2 authors contributed equally to this article, and both should be considered first author.
 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA (NIBSC 19/304) was obtained from the National Institute for Biological Standards and Control, United Kingdom. The following reagents were deposited by the US Centers for Disease Control and Prevention and obtained through BEI Resources, National Institute of Allergy and Infectious Diseases, US National Institutes of Health: SARS-related coronavirus 2, isolate USA-WA1/2020 NR-52281; SARS-related coronavirus 2, isolate hCoV-19/England/204820464/2020, NR-54000, contributed by Bassam Hallis; and SARS-related coronavirus 2, isolate hCoV-19/South Africa/KRISP-K005325/2020, NR-54009, contributed by Alex Sigal and Tulio de Oliveira. The authors were supported by the Austrian Science Fund (FWF; P34070-B to W.P. and P33510-B to D.W.), the Anniversary Fund of the Austrian National Bank (OeNB; P17614 to W.P., P17633 to D.W.), and the state of Tyrol (70454 to W.P.).
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2022  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 149 - N° 4

P. 1242 - avril 2022 Regresar al número
Artículo precedente Artículo precedente
  • Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19–convalescent individuals
  • Min Li, Jiaojiao Liu, Renfei Lu, Yuchao Zhang, Meng Du, Man Xing, Zhenchuan Wu, Xiangyin Kong, Yufei Zhu, Xianchao Zhou, Landian Hu, Chiyu Zhang, Dongming Zhou, Xia Jin
| Artículo siguiente Artículo siguiente
  • A unique population of neutrophils generated by air pollutant–induced lung damage exacerbates airway inflammation
  • Jae Woo Shin, Jihyun Kim, Seokjin Ham, Sun Mi Choi, Chang-Hoon Lee, Jung Chan Lee, Ji Hyung Kim, Sang-Heon Cho, Hye Ryun Kang, You-Me Kim, Doo Hyun Chung, Yeonseok Chung, Yoe-Sik Bae, Yong-Soo Bae, Tae-Young Roh, Taesoo Kim, Hye Young Kim

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.